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Abstract/Summary 
 
Breathlessness remains a challenging symptom, common to a multitude of malignant and non- 
malignant diseases, for which there are limited effective therapies once disease control is optimised. 
The American Thoracic Society (ATS) statement on dyspnoea reports that: 
i) Progress in dyspnoea management has not matched progress in elucidating underlying 
mechanisms; 
ii) There is a critical need for interdisciplinary translational research to connect dyspnoea 
mechanisms with treatments; 
iii) There is a need to validate dyspnoea measures as patient-reported outcomes for clinical 
trials. 
Research into the many dimensions of breathlessness and its significance to patients and their carers 
has increased in recent years. This meeting is convened yearly to bring together researchers across 
various disciplines including respiratory medicine, anaesthetics, medical humanities, engineering and 
palliative care, to further understanding of the symptom, discuss new techniques and advances in 
research, and pave the way forward for future studies and interventions. 
The presentations generated much vibrant discussion amongst the multidisciplinary attendees and 
highlighted areas where care for breathless patients could be improved. This is a positive time for 
breathlessness research, with several ATS research priorities being addressed and it is clear that 
further studies and ensuing interventions are on the horizon. 
Breathlessness is a symptom common to a multitude of malignant and non-malignant diseases. 
Even once disease control is optimised, there are limited effective therapies for this challenging 
symptom. The American Thoracic Society (ATS) statement on dyspnoea reports that: 
i) Progress in dyspnoea management has not matched progress in elucidating underlying 
mechanisms; 
ii) There is a critical need for interdisciplinary translational research to connect dyspnoea 
mechanisms with treatments; 
iii) There is a need to validate dyspnoea measures for use as patient-reported outcomes in 
clinical trials.1 
Research into the many dimensions of breathlessness and its significance to patients and their carers 
has increased in recent years.2 Although there are challenges to researching breathlessness, 
consensus does exist regarding a rational approach to designing adequately powered interventional 
studies, in order to allow future comparison between trials.3  This meeting is convened yearly to 
bring together researchers across various disciplines including respiratory medicine, anaesthetics, 
medical humanities, engineering and palliative care, to further understanding of the symptom, 
discuss new techniques and advances in research, and pave the way forward for future studies and 
interventions. 
 
Presentation 1 
 
Using MEG scanning to understand refractory breathlessness 
Prof Miriam Johnson 
Central (neural) mechanisms of breathlessness are yet to be fully understood. Although 
much has been elucidated with the advent of positron emission tomography (PET) and functional 
magnetic resonance imaging (fMRI), most studies have been on healthy volunteers using models of 
induced acute breathlessness.4 Magnetoencephalography (MEG) scanning is a form of functional 
brain imaging which detects changes in magnetic fields generated by the electrical currents caused 
by neuronal activity. It therefore differs from fMRI where changes in brain activity are inferred from 
measured changes in blood flow due to altered metabolic activity. MEG has advantages in terms of 
better patient tolerability, such as the ability to sit upright in the machine, and it allows direct 
measurement of neuronal activity in response to the patient’s circumstances for example, 
breathlessness induced by exercise which can be performed whilst seated in the scanner. 
Professor Johnson’s team are using MEG to study patients with chronic breathlessness and 
determine their neural responses to therapeutic interventions such as cool air across the face. They 
hope to develop methodology for future studies and confirm whether MEG imaging will be key to 
exploring the mechanisms by which patients perceive breathlessness. 
 
Presentation 2 
 
Neuroimaging of respiratory control in the human periaqueductal gray to understand brain 
mechanisms in breathlessness 
Dr Kyle Pattinson 
The brain is the final common pathway in various sensations such as pain, fear and 
breathlessness. Understanding the neural pathways involved will improve our understanding of 
breathlessness and therapies could potentially be targeted to these central mechanisms.4 
The periaqueductal gray (PAG) is a small structure located superiorly in the brainstem and as 
it sits at a junction between the cortex and brainstem, is key in the emotional and mechanical 
control of breathing. We know from animal models that the PAG is involved in active and passive 
coping strategies and through connectivity to other parts of the brain, its activity can be up- or 
down-regulated in response to different situations such as pain or breath-holding.5 Until recently, 
there have been difficulties with poor resolution of functional imaging of the area to elucidate PAG 
activity. However, Dr Pattinson’s group are investigating new imaging techniques including diffusion 
tractography (a form of MRI) to define PAG structure and activity and therefore provide greater 
understanding of the neurophysiology of breathlessness.6 
Presentation 3 
 
Pharmacological approaches to palliating breathlessness: what’s new? 
Prof David Currow 
Professor Currow provided an update on the evidence basis for three interventions for 
breathlessness: oxygen therapy, opioids and benzodiazepines, and nebulised opioids, and challenged 
aspects of current clinical practice. 
Most evidence suggests that oxygen does not have a role in the palliation of breathlessness.7 
Professor Currow drew our attention to a Cochrane systematic review which favoured oxygen over 
air for the reduction of breathlessness in people with COPD who did not qualify for home oxygen.8 
He also described a small study which showed that, although the majority of patients gained no 
additional symptomatic benefit from routine oxygen in the last hours or days of life, approximately 
10% of patients used oxygen to relieve distress from dypnoea, so there may be a role for oxygen in 
certain subgroups of patients.9 
Opioids have a well-established role in the palliation of breathlessness, with most evidence 
supporting regular, low dose, sustained-release oral morphine. Professor Currow and colleagues 
have studied the effect of long-acting morphine on breathlessness and found benefit, in a phase 2 
study up-titrating once daily sustained-release morphine, in approximately two-thirds of people.10 
Until recently, there has been little evidence to support the safety of opioids in advanced respiratory 
disease. However, in a large cohort study of 2249 patients with very severe COPD, it was observed 
that opioids at lower dose (≤30mg oral morphine per day) were not associated with increased 
mortality but higher doses were.11 Benzodiazepines were associated with increased mortality with a 
dose response trend. Although this study could not ascribe causality, neither benzodiazepines nor 
opioids were associated with increased hospital admission rates, and whilst concurrent 
benzodiazepine with low dose opioid usage was not associated with increased mortality, higher 
doses were.11 
Finally Professor Currow briefly talked about nebulised morphine and its potential role as a 
treatment for breathlessness. Although current limited evidence does not support this treatment, a 
small study of patients with breathlessness secondary to mustard gas exposure found benefit from 
once daily nebulised morphine without significant adverse effects.12 
Key Note Lecture 
 
Dyspnea: The First Vital Sign 
Prof Bob Banzett 
Professor Banzett proposed three “flavours” of dyspnoea which are described differently, 
manipulated independently and have different neural pathways.13 Dyspnoea is not a single sensation 
and can be thought of as comprising: 
1. Air hunger, 
2. Work/effort of breathing, 
3. Chest tightness. 
 
He affirmed the multidimensional nature of breathlessness with a sensory dimension and affective 
components. These include the distress caused by the unpleasantness of being breathless, and the 
emotional or evaluative responses that drive the accompanying feelings of fear and anxiety.14 
He described experiments his team have undertaken which show that patients can reliably 
rate their breathing discomfort and that there is good day-to-day consistency. The American 
Thoracic Society emphasises that dyspnoea can only be perceived by the person experiencing it.1 
Interestingly, it has been shown that clinicians usually underestimate dyspnoea.15 Further 
experiments show that free breathing, even with increased inspired CO2, is less uncomfortable than 
limited ventilation.16-18 Increasing a patient’s tidal volume relieves air hunger even when the ribcage 
and diaphragm are denervated due to cervical spine injuries.19 This supports the view that air hunger 
is a balance between respiratory drive and ventilation. Other experiments show that hypoxia must 
be profound to have significant effect on breathlessness.20 
Professor Banzett discussed the important evidence that dyspnoea is a better predictor of 
mortality and other adverse effects than FEV1 or other objective data.21,22 He described a pilot study 
in the USA involving nurses in a large teaching hospital in Boston recording dyspnoea in conjunction 
with the traditional vital signs. Efforts are being made to improve the methods used to measure 
dyspnoea and determine the ideal frequency of measurement.23  Dyspnoea is becoming recognised 
as a ‘vital symptom’ that impacts on patient outcomes. 
 
Presentation 4 
 
A feasibility study to adapt and develop a breathlessness intervention service (BIS) for people 
suffering from asbestosis in India: The SHWASS project 
 
Dr Helen Clayson 
 
Dr Clayson described a community-based volunteer-led educational programme using 
evidence-based, low-cost, low-technology, non-pharmacological interventions to try to improve 
breathlessness in former asbestos industry workers with asbestosis in Mumbai. The interventions 
trialled include exercise, fans, breathing control, positioning techniques, social support. They were 
evaluated with objective measures such as the 6-minute walk test and pulmonary function tests, as 
well as qualitative methods such as questionnaires and interviews. The project is still in progress and 
full evaluation has yet to be completed. However, there have been many learning points already 
including the importance of understanding cultural differences and how these affect research. 
Presentation 5 
 
Developing a complex non-pharmacological intervention for the respiratory symptom cluster of 
breathlessness, cough and fatigue in lung cancer 
 
Dr Janelle Yorke 
 
In lung cancer, the respiratory distress symptom cluster of breathlessness, cough and fatigue 
has been described by Molassiotis et al with breathlessness usually being the driving symptom of the 
cluster.24 An evidence base is developing for non-pharmacological management of single symptoms, 
but few have been developed and evaluated for symptom clusters. Given that the symptoms are 
usually present together, there is an argument that interventions should be targeted towards 
managing them concurrently in order to improve patients’ quality of life. Ellis et al have interviewed 
patients and results revealed that they would want flexible, practical interventions that would 
provide strategies to cope with different symptoms and specific problems, and that caregivers could 
be taught to carry out.25 This information aided development of a complex intervention for which Dr 
Yorke’s group have recently completed a study evaluating its feasibility and acceptability in 
management of the respiratory distress symptom cluster. Results are encouraging and warrant 
further investigation in a fully powered randomised controlled trial. 
 
Presentation 6 
 
The Life of Breath: A Medical Humanities approach to breathlessness. 
Prof Jane Macnaughton 
A medical humanities approach takes the view that biomedicine is unable to encompass and 
describe all aspects of breathlessness as there are significant emotional and existential components 
to the experience of this symptom. These components may, for example, be reflected in the 
metaphors exist surrounding breath, such as the first and last breath representing birth and death. 
The Wellcome Trust-funded Life of Breath project, which is a collaboration between Professor 
Macnaughton and Professor Havi Carel in Bristol, aims to provide an interdisciplinary understanding 
of the experience of breathing and breathlessness by bringing together historical, philosophical, 
anthropological and clinical research. It will investigate the cultural significances and historical origins 
of attitudes towards breathing, public health relationships, explore the phenomenology of breathing 
and breathlessness, and non-pathological versus pathological breathlessness. The aim is to impact 
upon the ways in which research on this symptom is carried out, and ultimately upon care and 
treatment. 
 
Presentation 7 
 
Data from the Living with Breathlessness study in COPD 
Dr Morag Farquhar 
The trajectory of COPD is that of a slow decline punctuated by acute exacerbations and 
contrasts significantly with that of lung cancer. There is a lack of research into the non-malignant 
disease trajectory. Dr Farquhar outlined the methods and components of the Living with 
Breathlessness study programme which seeks to address this knowledge gap, and presented 
baseline results from one component: the Longitudinal Interview Study. This is a mixed methods 
longitudinal study of a population-based cohort of 235 patients and 117 informal carers. The 
patients had moderate to severe breathlessness as characterised by mean MMRC dyspnoea scale 
and COPD Assessment Test (CAT). Patients experienced multiple symptoms including fatigue, cough, 
pain, anxiety, and depression. A notable proportion of these symptoms were not reported to a 
healthcare professional: anxiety and depression in particular. The needs of informal carers are also 
being investigated using the Carer Support Needs Assessment Tool (CSNAT) alongside other carer 
variables such as their preparedness for caregiving. Dr Farquhar presented findings on patients’ 
service access and views of care. The research aims to identify drivers for service delivery as well as 
met and unmet needs amongst patients and carers. 
 
Presentation 8 
 
Learning about breathlessness study 
Dr Clarissa Penfold 
Breathlessness is a distressing, disabling symptom of advanced disease with considerable 
impact on informal carers. Carers experience anxiety, isolation, restriction of activity, lack of support 
and powerlessness. The Learning about Breathlessness study, led by Dr Morag Farquhar, seeks to 
understand educational needs of carers. In particular, the study is exploring carer preferences for 
learning content and delivery modes for an educational intervention to support informal carers and 
enhance their caregiving capacity. Qualitative in-depth interviews were conducted with a purposive 
sample of 24 patient-carer dyads. Despite different disease trajectories (cancer and COPD), 
preliminary results suggest that there are similarities in carer preferences for content and delivery 
mode. Workshops with clinical-practitioner experts and informal carers will draw on these interview 
findings to co-develop an educational intervention. Finally, an online survey of clinicians will identify 
clinician-relevant outcomes for a future RCT of the co-developed intervention. 
 
Presentation 9 
 
Brief update on breathlessness and its relationship with the HPA axis 
Dr Richella Ryan 
Breathlessness tends to be experienced as a threat to survival, suggesting involvement of 
the stress system. Dr Ryan and her colleagues are exploring the role of the hypothalamic-pituitary- 
adrenal (HPA) axis in breathlessness, hypothesising that chronic breathlessness causes over- 
activation of the HPA axis, with resultant dysregulation of diurnal cortisol secretion. They are 
currently conducting a feasibility study in which salivary diurnal cortisol levels are measured in 
patients with chronic breathlessness, both before and after an intervention (ISRCTN70836126). 
Though this is early work, it is exciting to consider the potential of this system as a biomarker for the 
evaluation of breathlessness therapies within clinical trials. 
 
 
Conclusion 
This meeting demonstrates the wide variety of research being carried out in the field of 
breathlessness addressing a spectrum of issues from understanding biological mechanisms to 
patient and carer experiences, and attempting to disseminate the knowledge to communities with 
fewer resources. Each year more areas of research are introduced and progress in managing the 
symptom is evident. However, breathlessness management and research still lags behind that for 
other symptoms such as pain, and larger studies in different subgroups of patients are needed. The 
presentations generated vibrant discussion amongst the multidisciplinary attendees and highlighted 
areas where care for breathless patients could be improved. This is a positive time for 
breathlessness research, with several of the ATS research priorities being addressed and it is clear 
that further important studies and innovative interventions are on the horizon. 
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